CoChat

Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes

Open access
Trujillo, Jennifer · 2020 · Journal of Clinical Pharmacy and Therapeutics
Cited by 130

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

WHAT IS KNOWN AND OBJECTIVE: In recent years, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) including once-weekly (QW) formulations have been incorporated into type 2 diabetes (T2D) clinical guidelines, making it essential that pharmacists and healthcare professionals (HCPs) have a clear understanding of their safety profiles. Currently, three QW GLP-1 RAs are approved and marketed in the United States for the treatment of T2D: dulaglutide, exenatide extended-release and semaglutide. This review provides pharmacists and HCPs with collated data related to potential safety and tolerability issues when patients use QW GLP-1 RAs, enabling patient education and treatment optimization. METHODS: This is a narrative review comparing the safety and tolerability of the three QW GLP-1 RAs, using data from Phase 3 clinical trials. Extracted safety data included gastrointestinal (GI) adverse events (AEs), hypoglycaemia, injection-site reactions, pancreatitis, neoplasms, gallbladder events, and diabetic retinopathy (DR) and/or its complications (DRCs). RESULTS AND DISCUSSION: A total of 30 trials were identified for inclusion; eight were head-to-head trials involving another GLP-1 RA; of these, six compared GLP-1 RAs with different dosing regimens (QW vs once-daily or twice-daily), and two were direct QW vs QW GLP-1 RA comparisons. The most commonly reported AEs were GI events (notably nausea, vomiting and diarrhoea), but there was variation between the three QW drugs. These were generally mild-to-moderate in severity and transient. Risk of hypoglycaemia, injection-site reactions, pancreatitis, neoplasms and gallbladder events was generally low across the GLP-1 RAs investigated. Overall rates of DR or DRC were low across the trials. Only in one trial (SUSTAIN 6) there were significantly more DRC events reported in patients treated with QW semaglutide (3.0%) compared with placebo (1.8%). This was likely due to the rapid improvement in glucose control in patients with pre-existing DR enrolled within that trial. WHAT IS NEW AND CONCLUSION: This review puts the latest clinical data from the marketed QW GLP-1 RAs into context with results from older Phase 3 trials, to enable pharmacists and HCPs to make informed treatment decisions. Each of the three QW GLP-1 RAs has their own safety profile, which should be considered when choosing the optimal treatment for patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jcpt.13225

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Research works printed but not linked: 36

  1. 10.1016/S0140-6736(18)32279-7 · DOI · Paper page
  2. 10.1016/S0140-6736(13)62154-6 · DOI · Paper page
  3. Buse JB, 2018, A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care, 2020, 487
  4. 10.18553/jmcp.2018.24.9-a.s5 · DOI · Paper page
  5. 10.1038/nrendo.2009.48 · DOI · Paper page
  6. 10.2337/dc09-S315 · DOI · Paper page
  7. 10.1111/dom.12849 · DOI · Paper page
  8. 10.1016/S0140-6736(14)61335-0 · DOI · Paper page
  9. 10.1111/dom.12596 · DOI · Paper page
  10. 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
  11. 10.1056/NEJMoa1612917 · DOI · Paper page
  12. 10.1089/dia.2014.0188 · DOI · Paper page
  13. 10.1016/S0140-6736(15)60936-9 · DOI · Paper page
  14. 10.1016/S2213-8587(18)30104-9 · DOI · Paper page
  15. 10.1016/S2213-8587(17)30085-2 · DOI · Paper page
  16. 10.2337/dc13-2759 · DOI · Paper page
  17. 10.2337/dc11-1107 · DOI · Paper page
  18. 10.1016/S0140-6736(10)60590-9 · DOI · Paper page
  19. 10.1016/S2213-8587(19)30311-0 · DOI · Paper page
  20. 10.1016/S0140-6736(12)61267-7 · DOI · Paper page
  21. 10.1016/S2213-8587(18)30024-X · DOI · Paper page
  22. 10.1111/dom.12634 · DOI · Paper page
  23. 10.1111/dom.13266 · DOI
  24. 10.1016/S2213-8587(16)30267-4 · DOI · Paper page
  25. 10.2337/db14-0883 · DOI
  26. 10.1152/ajpgi.00293.2015 · DOI
  27. 10.1007/s12020-014-0386-8 · DOI
  28. 10.1111/dom.12386 · DOI · Paper page
  29. 10.2337/dc08-1755 · DOI · Paper page
  30. 10.1016/j.dld.2003.10.007 · DOI
  31. 10.1111/dom.13172 · DOI · Paper page
  32. 10.1016/S0828-282X(08)71019-5 · DOI
  33. 10.1111/dom.13331 · DOI
  34. 10.1056/NEJMoa1903822 · DOI · Paper page
  35. 10.1161/CIRCULATIONAHA.117.032759 · DOI
  36. 10.1111/dom.13484 · DOI

Cited by

See all 130

Metadata

Authors
Trujillo, J.
Venue
Journal of Clinical Pharmacy and Therapeutics
Publisher
Wiley
Published
2020-09
Volume
45
Issue
S1
Pages
43-60
ISSN
  • 0269-4727 (ISSN-L)
  • 1365-2710
OpenAlex
W3086646659
Cited by
130
References
34
FWCI
7.16
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes. https://app.cochat.ai/papers/10.1111/jcpt.13225
The paper
Trujillo, J. (2020). Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics. https://doi.org/10.1111/jcpt.13225

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.